POPULATION PHARMACOKINETIC AND EXPOSURE-RESPONSE ANALYSES OF A PHASE 1 STUDY OF SUTIMLIMAB IN PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA.

被引：0
|
作者：
Chow, T. [1 ]
Daak, A. [1 ]
Lu, Q. [2 ]
Wong, N. [1 ]
机构：
[1] Sanofi, Waltham, MA USA
[2] Sanofi, Bridgewater, NJ USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2022年 / 111卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
P-038
引用
收藏
页码：S15 / S15
页数：1
相关论文
共 50 条
  • [21] Population Pharmacokinetics and Exposure-Response Analyses of Sarilumab in Patients with Polymyalgia Rheumatica
    Xu, Christine
    Denney, William S.
    Liu, Ying
    Sloane, Jennifer
    Diab, Remco
    Abdallah, Hisham
    Macha, Sreeraj
    Dasgupta, Bhaskar
    JOURNAL OF CLINICAL PHARMACOLOGY, 2025,
  • [22] Population modeling of bosutinib exposure-response in patients with newly diagnosed chronic phase chronic myeloid leukemia
    Garrett, May
    Knight, Beverly
    Cortes, Jorge E.
    Deininger, Michael W.
    CANCER MEDICINE, 2023, 12 (17): : 17981 - 17992
  • [23] Development of a Population Pharmacokinetic Model for Binimetinib with Subsequent Exposure-Response Analyses in NRAS Mutant Melanoma
    Wollenberg, Lance
    Marchand, Mathilde
    Merdjan, Henri
    Litwiler, Kevin
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2018, 45 : S69 - S69
  • [24] Pharmacokinetic and exposure-response analyses for extrapolation of efficacy of adalimumab in adolescent patients with hidradenitis suppurativa
    Nader, A.
    Kluender, B.
    Kwatra, N. V.
    Wegzyn, C.
    Mostafa, N. M.
    EXPERIMENTAL DERMATOLOGY, 2017, 26 : 29 - 29
  • [25] Population pharmacokinetic and exposure-response safety analyses of mecbotamab vedotin (BA3011) in patients with advanced solid tumors
    Shen, Guoxiang George
    Briggs, Emily
    Crass, Ryan
    Karumanchi, Sravan
    Boyle, William J.
    Baker, Michael G.
    Martin, Philippe
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [26] Population Pharmacokinetics and Exposure-Response Analyses for Risankizumab in Patients with Active Psoriatic Arthritis
    Thakre, Neha
    D'Cunha, Ronilda
    Goebel, Aline
    Liu, Wei
    Pang, Yinuo
    Suleiman, Ahmed A.
    RHEUMATOLOGY AND THERAPY, 2022, 9 (06) : 1587 - 1603
  • [27] Pimavanserin Exposure-Response Analyses in Patients With Schizophrenia Results From the Phase 2 ADVANCE Study
    Darwish, Mona
    Bugarski-Kirola, Dragana
    Passarell, Julie
    Owen, Joel
    Jaworowicz, David
    DeKarske, Daryl
    Stankovic, Srdjan
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2022, 42 (06) : 544 - 551
  • [28] Population pharmacokinetics and exposure-response modeling analyses of guselkumab in patients with psoriatic arthritis
    Chen, Yang
    Miao, Xin
    Hsu, Chyi-Hung
    Zhuang, Yanli
    Kollmeier, Alexa
    Xu, Zhenhua
    Zhou, Honghui
    Sharma, Amarnath
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2022, 15 (03): : 749 - 760
  • [29] Population pharmacokinetic and exposure-response analyses for efficacy and safety of risankizumab in subjects with active Crohn's disease
    Suleiman, A.
    Goebel, A.
    Bhatnagar, S.
    D'Cunha, R.
    Liu, W.
    Pang, Y.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I514 - I516
  • [30] Population pharmacokinetic and exposure-response analyses of elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory multiple myeloma
    Ide, Takafumi
    Osawa, Mayu
    Sanghavi, Kinjal
    Vezina, Heather E.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022, 89 (01) : 129 - 140
12345